Schrodinger, Inc. (SDGR): Cash & Equivalents
$230.52M
As of 2025-12-31
$287.85M
As of 2026-06-30
+36.6%
3-year compound annual growth
+2.6%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $230.52M | +56.5% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $147.33M | -5.1% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $155.31M | +71.7% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $90.47M | -24.8% | 2024-02-28, Balance as of period end |
| 2021-12-31 | $120.27M | -40.5% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $202.30M | +678.5% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $25.99M | n/a | 2021-03-04, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $230.52M | +56.5% |
| Arvinas, Inc. (ARVN) | 2025-12-31 | $142.90M | +42.2% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $222.00M | +48.0% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $174.93M | +141.9% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $287.42M | -48.7% |
| Harrow, Inc. (HROW) | 2025-12-31 | $72.93M | +54.4% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $184.84M | +256.4% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $238.20M | +93.5% |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $29.64M | -57.2% |
Compare SDGR, ARVN, RCUS, LGND side by side · Screen every company in Pharmaceutical Preparations ↗